Press release
New Partner at Market Research Portal RE:SEARCH
RE:SEARCH GmbH
Market information is the lifeblood of any company: not just information, but the insight and intuition that go with it. Every year, Datamonitor helps people in 5,000 of the World’s leading businesses with exactly this. Whether it’s information for new products, M&A, restructuring, investing or overall market awareness, Datamonitor provide the kind of service quality and sophistication of data that few can match. The result is the customers are able to make more confident decisions, bolder plans and ultimately deliver better profits. Datamonitor’s research products feature primary data, independent analysis and fresh opinions on markets, trends and players.
Datamonitor’s energy portfolio provides information on different aspects in Forecourt Retailing and Utilities, Renewable Energy, Alternative Energy sources across various markets in Europe and the emerging markets.
RE:SEARCH offers a webportal for market research studies in the area of cleantech, energy efficiency and renewable energy. The company is eager to offer its customers one of the most comprehensive databases of market reports to provide its customers an excellent overview about the cleantech industry.
Moreover, clients have access to a keyword-driven search engine which scans hundreds of important sites on the internet for free reports. Additionally, RE:SEARCH expands the database with further reports like executive summaries. To find special information clients may also place an individual inquiry according to their special needs.
Gunnar Kersten
RE:SEARCH® GmbH
Moltkestraße 123 – 131
50674 Köln
Germany
Fon: +49-(0)221-80006150
Fax: +49-(0)221-80006153
web: www.renewable-energy-search.com
e-mail: info@renewable-energy-search.com
This release was published on openPR.
Permanent link to this press release:
Copy
Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.
You can edit or delete your press release New Partner at Market Research Portal RE:SEARCH here
News-ID: 95705 • Views: …
More Releases from RE:SEARCH GmbH
Cleantech portal RE:SEARCH now free of charge
Cologne 09/17/2009: Searching significant and up-to-date information on the internet costs a lot of time and work and often leads to unrequested results. To identify quickly what fits the needs RE:SEARCH developed a keyword-driven search engine for information about all aspects of the cleantech business. After registering for free, clients have now unlimited access to this helpful and valuable service. The search engine scans hundreds of important sites on the…
Success for new market portal RE:SEARCH at Intersolar
Munich, 06/12/09: The new market portal for research studies in the area of Cleantech and Renewable Energy has successfully launched. At Intersolar a strong interest from the audience attested to the need for a comprehensive source of know-how for the fast-paced Cleantech market. The special offer for new clients has been extended.
CEO Arne Wittmer reports the first presentation of the new portal www.renewable-energy-search.com at Intersolar in Munich was a successful…
Cleantech portal RE:SEARCH launched! Market research reports at a glance
Cologne, 05/15/09: In the fast-moving Cleantech industry it is absolutely necessary to identify market developments quickly and efficiently. The German company RE:SEARCH has therefore launched the new B2B-website www.renewable-energy-search.com. This platform provides companies working in the field of Cleantech and Renewable Energy the opportunity to receive a huge variety of up-to-date market reports and to gain greater insights into upcoming market developments at a glance. Furthermore clients are welcome to…
More Releases for Datamonitor
Datamonitor: MannKind - FDA's second rejection casts doubt on Afrezza's future
The FDA has requested further Phase III trials of MannKind's inhaled insulin Afrezza with its next generation Dreamboat inhaler before it can be approved. Should it eventually receive approval, Afrezza is likely to attract only a niche patient population, and Datamonitor forecasts that it will garner low sales compared to its competitors, due to safety fears and limited demand for inhaled insulin.
MannKind has announced a further delay for its inhaled…
Datamonitor: Australia - election outcome offers renewed hope for pharmaceutical …
Earlier in 2010, Medicines Australia negotiated a Memorandum of Understanding with the Labor government which was meant to provide stability for Australia's pharmaceutical industry. However, the election and subsequent hung parliament delayed its implementation. Now, with the Labor Party once more seated in power, Datamonitor expects the government to move forward with the existing agreement.
More than two weeks after the Australian election resulted in a hung parliament, Julia Gillard's Labor…
Datamonitor: Greece - pharmaceutical companies take a stand over pricing
Following the publication of a new pricing bulletin which aims to cut healthcare costs in Greece, a significant proportion of pharmaceutical companies currently operating in the country have challenged the new prices. While there are many ways in which companies can beat the new pricing laws, the regulations may prove harmful to pharmaceutical company sales in Greece and, indeed, across Europe.
The battle continues to rage between pharmaceutical companies and the…
Datamonitor: ATS 2010 - developments in IPF and cystic fibrosis
The FDA's recent refusal of Esbriet and the publication of new guidelines for the treatment of idiopathic pulmonary fibrosis drove considerable interest in this disease at the 2010 meeting of the American Thoracic Society. Furthermore, the approval of the first new inhaled antibiotic for cystic fibrosis in over a decade brought renewed focus on this rare but extremely debilitating disease.
Idiopathic pulmonary fibrosis (IPF) is an often fatal form of interstitial…
Datamonitor: Commercial Insight - Antihormonal Cancer Therapies on reports-resea …
Antihormonal cancer therapies are a class of drugs used predominantly in the treatment of breast cancer and prostate cancer. The high incidence of these tumor types translates into a significant commercial potential for drug developers. Collectively, the antihormonal therapy cancer brands generated sales of about $6.9 billion in the seven major pharmaceutical markets in 2008.
Research and analysis highlights
The antihormonals market was worth $6.9 billion in 2008 across the seven major…
Datamonitor: Commercial Insight - Cytotoxic Therapies on reports-research.com
Despite the advent of molecular targeted therapies, cytotoxic chemotherapy remains the cornerstone of cancer treatment and is used across nearly the entire spectrum of tumor types. A number of cytotoxic drugs are on the market, however only a few currently dominate in terms of revenues, with Taxotere (docetaxel; Sanofi-Aventis), Eloxatin (oxaliplatin; Sanofi-Aventis) and Gemzar (gemcitabine; Eli Lilly) the three leading cytotoxics in terms of sales in 2008, with 7MM annual…
